Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Conditions
Brief summary
CDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful strategy in these chemotherapy and immunotherapy resistant diseases.
Detailed description
This is a multicenter, open label, phase I/II safety study that will enroll 30 subjects with metastatic esophageal and gastroesophageal junction adenocarcinomas post first line systemic chemotherapy. Subjects will be treated with oral Abemaciclib 150 mg PO daily bid given with ramucirumab 8mg/kg every 2 weeks iv until evidence of disease progression or unacceptable toxicities. A total of 30 subjects will be enrolled. The primary goal is to describe the safety profile of Abemaciclib in combination with Ramucirumab among all enrolled subjects. If grade 3 or higher treatment-related adverse events occur in 20 subjects, the upper bound of 95% Wilson confidence interval for the adverse event rate would be below 81% (16.7% - 47.9%). The safety analysis will be performed in all treated subjects. Adverse event data will be listed individually and graded according to the National Cancer Institute Common Terminology Criteria, version 4.03. Summary statistics will include counts and proportions as well as rates with 95% confidence intervals. Toxicities will be reported as a tabulated table by type and grade. Objective response rate is defined as the percentage of subjects who achieve an objective response by RECIST1.1 criteria (i.e. Complete response or Partial Response) to Abemaciclib in combination with Ramucirumab. We will estimate the objective response rate, along with the Wilson 95% confidence interval, for the population of subjects. Overall survival will be defined as the time from study enrollment to death. This will be summarized using a Kaplan-Meier curve. The proportion of subjects with grade 4 or higher treatment-related adverse events will be monitored continuously throughout the trial using a Bayesian stopping guideline. A Beta (1, 19) prior, representing a toxicity rate of 5%, slightly lower than the expected rate of 6%, was used in the development of our guidelines. The therapy will be re-evaluated if the posterior probability that the toxicity rate exceeds 10% is greater than 75%. Table 3 summarizes the stopping boundaries starting with the initial cohort of 3 subjects through the maximum sample size of 30 subjects. The probability of triggering the stopping guidelines was assessed for a range of possible toxicity rates using simulations with 5000 replicates. The probability of stopping to re-evaluate was 1% if the true proportion with an unacceptable toxicity was 5%. In comparison, the probability of stopping early was 99.6% if the true proportion with an unacceptable toxicity was 40%
Interventions
DRUGAbemaciclib
150mg dose administered orally twice daily every day
DRUGRamucirumab
8mg/kg iv every 2 weeks until evidence of disease
Sponsors
Baylor Research Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Subjects must meet all eligibility criteria. The key inclusion and
Exclusion criteria
are as follows: Key Inclusion Criteria: * All subjects must have metastatic esophageal or gastroesophageal junction carcinomas (adenocarcinoma only) * ECOG performance status of 0 or 1 * Tumor tissue must be available for correlative studies - Either a formalin fixed paraffin block or a minimum of ten 5-micron tissue section's (slides) of tumor biopsy sample must be available for biomarker evaluation. * Patients must have received at least one prior line of standard systemic therapy for recurrent or Stage IV disease, and that patients with HER2 overexpression have received an anti-HER2 drug. Key
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of Abemaciclib + Ramucirumab | From date of study enrollment, through treatment, and during follow-up until 100-days after the last dose of study medication or death, from any cause, whichever occurred first, assessed up to 24 months | The safety profile was assessed by counting the number of patients who experienced adverse events (AEs) and serious adverse events (SAEs) of Grade 3 or higher while on study using CTCAE v4.0 criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | From date of study enrollment until the date of death, from any cause, assessed up to 24 months | Objective response rate is defined as the number of subjects who achieve an objective response by RECIST1.1 criteria (i.e., Complete Response or Partial Response) to Abemaciclib in combination with Ramucirumab. |
| Progression Free Survival | From date of study enrollment until the date of first radiographic tumor progression or death from any cause, whichever came first, assessed up to 24 months. | The duration of progression-free survival is measured from the time of randomization to radiographic tumor progression or death. |
| Overall Survival | From date of study enrollment until the date of death, from any cause, assessed up to 24 months | Overall survival will be defined as the time from study enrollment to death. |
| Rate of Stable Disease | At 3 months after targeted therapy initiation | Rate of stable disease is defined as having a reading of stable disease or better per RECIST 1.1 criteria. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORRonan Kelly, MD
Charles A Sammons Cancer Center/Texas Oncology
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 61 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 25 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 26 Participants |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 24 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 11 / 26 |
| other Total, other adverse events | 17 / 26 |
| serious Total, serious adverse events | 6 / 26 |
Outcome results
None listed